Deals & Cases
Schellenberg Wittmer successfully represented Actavis in patent litigation against Eli Lilly
09.03.2017
Actavis, an affiliate of Teva Pharmaceutical Industries, one of the leading pharmaceutical companies worldwide, was successfully represented in a patent litigation by Schellenberg Wittmer’s IP Team (lead counsel Andrea Mondini) against Eli Lilly.
After having dismissed Eli Lilly's request for preliminary injunctions, the Swiss Federal Patent Court granted Actavis a declaratory judgment on the merits that Actavis' pemetrexed diacid product does not infringe Eli Lilly's patent EP 1 313 508 B1 claiming pemetrexed disodium for cancer treatment. This patent is heavily litigated in several countries, including Germany and the United Kingdom.
Teilen
Weitere Informationen
bundespatentgericht.chKontakt
Schellenberg Wittmer berät Emerald Technology Ventures im Zusammenhang mit FINMA-Bewilligung
13.02.2024
Schellenberg Wittmer berät Carne bei der Übertragung der Third-Party Fund Management Services von GAM
01.02.2024
Schellenberg Wittmer berät AXA bei der Vereinigung ihrer drei Immobilienfonds
30.01.2024